PROVECTUS BIOPHARMACEUTICALS, INC. Quarterly Operating Income (Loss) in USD from Q2 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Provectus Biopharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2010 to Q2 2024.
  • Provectus Biopharmaceuticals, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$795K, a 0.67% increase year-over-year.
  • Provectus Biopharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$2.56M, a 12.7% increase year-over-year.
  • Provectus Biopharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$2.9M, a 15.4% increase from 2022.
  • Provectus Biopharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$3.43M, a 26.6% increase from 2021.
  • Provectus Biopharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$4.67M, a 5.87% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$2.56M -$795K +$5.35K +0.67% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$2.57M -$447K +$335K +42.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$2.9M -$605K +$79K +11.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$2.98M -$714K -$48K -7.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$2.93M -$800K +$278K +25.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$3.21M -$782K +$218K +21.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$3.43M -$684K +$539K +44.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$3.97M -$666K +$381K +36.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$4.35M -$1.08M +$144K +11.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$4.49M -$1M +$181K +15.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$4.67M -$1.22M -$19.7K -1.64% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$4.65M -$1.05M +$54.6K +4.96% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$4.71M -$1.22M -$11.2K -0.92% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$4.7M -$1.18M +$268K +18.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$4.96M -$1.2M +$18.3K +1.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-29
Q3 2020 -$4.98M -$1.1M +$341K +23.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$5.32M -$1.21M +$629K +34.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$5.95M -$1.45M +$348K +19.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 -$6.3M -$1.22M +$681K +35.8% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-02
Q3 2019 -$6.98M -$1.44M -$85.1K -6.26% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$6.9M -$1.84M +$256K +12.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 -$7.15M -$1.8M +$903K +33.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-13
Q4 2018 -$8.05M -$1.9M +$723K +27.5% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-05
Q3 2018 -$8.78M -$1.36M +$1.64M +54.6% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$10.4M -$2.09M +$1.21M +36.6% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 -$11.6M -$2.7M +$1.7M +38.6% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
Q4 2017 -$13.3M -$2.63M +$2.56M +49.4% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 -$15.9M -$2.99M +$2.78M +48.2% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 -$18.7M -$3.3M +$1.74M +34.5% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$20.4M -$4.4M +$4.11M +48.3% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 -$24.5M -$5.18M +$4.48M +46.4% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-23
Q3 2016 -$29M -$5.78M +$1.74K +0.03% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 -$29M -$5.04M -$453K -9.87% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 -$28.5M -$8.51M -$3.89M -84.1% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q4 2015 -$24.7M -$9.66M -$9.4M -3535% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-31
Q3 2015 -$15.3M -$5.78M -$1.95M -51.1% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-09
Q2 2015 -$13.3M -$4.59M -$432K -10.4% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 -$12.9M -$4.62M -$239K -5.45% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 -$12.6M -$266K +$2.58M +90.7% Oct 1, 2014 Dec 31, 2014 10-K 2017-03-31
Q3 2014 -$15.2M -$3.83M -$176K -4.81% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-05
Q2 2014 -$15M -$4.16M -$873K -26.6% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-06
Q1 2014 -$14.2M -$4.38M -$1.13M -34.9% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-07
Q4 2013 -$13M -$2.84M -$591K -26.2% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-12
Q3 2013 -$12.4M -$3.65M -$56K -1.56% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-12
Q2 2013 -$12.4M -$3.29M +$998K +23.3% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-12
Q1 2013 -$13.4M -$3.25M +$958K +22.8% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-12
Q4 2012 -$14.3M -$2.25M +$2.15M +48.8% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-13
Q3 2012 -$16.5M -$3.59M +$3.88M +51.9% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-13
Q2 2012 -$20.4M -$4.29M +$1.09M +20.3% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-13
Q1 2012 -$21.5M -$4.21M -$12K -0.29% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-13
Q4 2011 -$21.4M -$4.4M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-14
Q3 2011 -$7.47M -$31.2K -0.42% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-14
Q2 2011 -$5.38M +$143K +2.59% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-14
Q1 2011 -$4.19M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-14
Q3 2010 -$7.44M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-08
Q2 2010 -$5.52M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.